Spero Therapeutics, Inc. Contracts & Agreements

Consulting Agreement, effective as of August 29, 2024, by and between the Registrant and Kamal Hamed (Filed With SEC on November 14, 2024)

Separation Agreement, dated July 30, 2024, by and between the Registrant and Kama Hamed (Filed With SEC on November 14, 2024)

Consulting Agreement, effective as of August 5, 2024, by and between the Registrant and John C. Pottage, Jr., M.D (Filed With SEC on November 14, 2024)

Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on November 14, 2024)

Employment Agreement, dated October 31, 2023, by and between the Registrant and Esther Rajavelu (Filed With SEC on May 15, 2024)

Amendment 3 to Exclusive License Agreement, dated March 4, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on May 15, 2024)

2019 Inducement Equity Incentive Plan, as amended (Filed With SEC on March 13, 2024)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 13, 2024)

Separation Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph (Filed With SEC on March 13, 2024)

Consulting Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph (Filed With SEC on March 13, 2024)

Amendment 1 to Exclusive License Agreement, dated July 4, 2023, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on March 13, 2024)

Amendment 2 to Exclusive License Agreement, dated December 20, 2023, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on March 13, 2024)

Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (Filed With SEC on October 10, 2023)

Transition and Separation Agreement, dated June 13, 2023, by and between the Registrant and Ankit Mahadevia, M.D (Filed With SEC on August 10, 2023)

Consulting Agreement, dated June 13, 2023, by and between the Registrant and Ankit Mahadevia, M.D (Filed With SEC on August 10, 2023)

Amended and Restated Employment Agreement, dated June 13, 2023, by and between the Registrant and Satyavrat Shukla (Filed With SEC on August 10, 2023)

Consulting Agreement, dated June 12, 2023, by and between the Registrant and Danforth Advisors, LLC (Filed With SEC on August 10, 2023)

Second Amendment to Employment Agreement, dated as of February 1, 2023, by and between the Registrant and Timothy Keutzer (Filed With SEC on May 11, 2023)

Amendment 1 to Consulting Agreement, dated August 4, 2022, by and between the Registrant and Cristina Larkin (Filed With SEC on November 14, 2022)

Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (Filed With SEC on September 19, 2022)

Separation Agreement, dated May 3, 2022, by and between the Registrant and Cristina Larkin (Filed With SEC on August 10, 2022)

Separation Agreement, dated May 3, 2022, by and between the Registrant and David Melnick, M.D (Filed With SEC on August 10, 2022)

Consulting Agreement, dated May 3, 2022, by and between the Registrant and Cristina Larkin (Filed With SEC on August 10, 2022)

Consulting Agreement, dated May 3, 2022, by and between the Registrant and David Melnick, M.D (Filed With SEC on August 10, 2022)

Revenue Interest Termination Agreement, dated June 7, 2022, by and between Spero Therapeutics, Inc., entities managed by HealthCare Royalty Management, LLC and HCR Collateral... (Filed With SEC on June 7, 2022)

Description of Registrants Securities (Filed With SEC on March 31, 2022)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 31, 2022)

Revenue Interest Financing Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and entities managed by HealthCare Royalty Management, LLC (Filed With SEC on September 30, 2021)

Security Agreement, dated September 29, 2021, by and between Spero Therapeutics, Inc. and HCR Collateral Management, LLC (Filed With SEC on September 30, 2021)

Form of Restricted Stock Unit Agreement under the 2017 Stock Incentive Plan, as amended (Filed With SEC on August 30, 2021)

Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (Filed With SEC on August 18, 2021)

License Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc (Filed With SEC on August 5, 2021)

Share Purchase Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc (Filed With SEC on August 5, 2021)

Employment Agreement, dated December 9, 2020, by and between the Registrant and Satyavrat Shukla (Filed With SEC on March 11, 2021)

Employment Agreement, dated November 6, 2020, by and between the Registrant and Tamara Joseph (Filed With SEC on March 11, 2021)

Amended and Restated License Agreement, dated January 15, 2021, by and between the Registrant and Everest Medicines II Limited (Filed With SEC on March 11, 2021)

Controlled Equity Offering Sales Agreement, dated March 11, 2021, by and between the Registrant and Cantor Fitzgerald & Co (Filed With SEC on March 11, 2021)

Underwriting Agreement, dated September 10, 2020, between Spero Therapeutics, Inc. and Cowen and Company, LLC and Evercore Group, L.L.C., as representatives of the several... (Filed With SEC on September 14, 2020)

2019 Inducement Equity Incentive Plan, as amended (Filed With SEC on August 6, 2020)

Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan, as amended (Filed With SEC on August 6, 2020)

Amended and Restated Employment Agreement, dated April 22, 2020, by and between the Registrant and Thomas Parr Jr., Ph.D (Filed With SEC on August 6, 2020)

Third Amendment to Lease Agreement, dated May 4, 2020, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC (Filed With SEC on August 6, 2020)

Consulting Agreement, dated November 4, 2019, by and between the Registrant and Danforth Advisors, LLC (Filed With SEC on May 8, 2020)

Description of Registrants Securities (Filed With SEC on March 16, 2020)

Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 16, 2020)

Employment Agreement, dated January 1, 2020, by and between the Registrant and Timothy Keutzer (Filed With SEC on March 16, 2020)

Consulting Agreement, dated April 18, 2019, by and between the Registrant and David P. Southwell (Filed With SEC on March 16, 2020)

Investment Agreement, dated January 30, 2020 (Filed With SEC on January 30, 2020)

Securities Purchase Agreement, dated as of June 12, 2019, by and between Spero Therapeutics, Inc. and Novo Holdings A/S (Filed With SEC on August 8, 2019)

Securities Purchase Agreement, dated as of June 12, 2019, by and between Spero Therapeutics, Inc. and Novo Holdings A/S (Filed With SEC on June 13, 2019)

2019 Inducement Equity Incentive Plan (Filed With SEC on March 14, 2019)

Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on March 14, 2019)

License Agreement, dated January 4, 2019, by and between New Pharma License Holdings Limited and Everest Medicines II Limited (Filed With SEC on March 14, 2019)

Exchange Agreement by and among Spero Therapeutics, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and MSI... (Filed With SEC on November 16, 2018)

Form of Underwriting Agreement (Filed With SEC on July 11, 2018)

Form of Underwriting Agreement (Filed With SEC on July 9, 2018)

Employment Agreement, dated December 13, 2017, by and between the Registrant and David Melnick, M.D (Filed With SEC on April 2, 2018)

Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (Filed With SEC on December 14, 2017)

Form of Stock Option Agreement under the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (Filed With SEC on December 14, 2017)

Form of Underwriting Agreement (Filed With SEC on October 23, 2017)

Employment Agreement, dated October 20, 2017, by and between the Registrant and Ankit Mahadevia, M.D (Filed With SEC on October 23, 2017)

Employment Agreement, dated October 20, 2017, by and between the Registrant and Joel Sendek (Filed With SEC on October 23, 2017)

Employment Agreement, dated October 20, 2017, by and between the Registrant and Thomas Parr Jr., Ph.D (Filed With SEC on October 23, 2017)

Employment Agreement, dated October 20, 2017, by and between the Registrant and Cristina Larkin (Filed With SEC on October 23, 2017)

Assignment and License Agreement, dated May 9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on October 23, 2017)

Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.) (Filed With SEC on October 23, 2017)

Form of Proprietary Information and Inventions Assignment Agreement (Filed With SEC on October 23, 2017)

2017 Stock Incentive Plan, as amended (to become effective upon completion of this offering) (Filed With SEC on October 23, 2017)

Form of Stock Option Agreement under 2017 Stock Incentive Plan, as amended (to become effective upon completion of this offering) (Filed With SEC on October 23, 2017)

Non-Employee Director Compensation Policy (Filed With SEC on October 23, 2017)

Form of Common Stock Certificate (Filed With SEC on October 6, 2017)

Investors Rights Agreement, dated as of June 30, 2017, by and between the Registrant and the other parties thereto (Filed With SEC on October 6, 2017)

2017 Stock Incentive Plan (Filed With SEC on October 6, 2017)

Form of Stock Option Agreement under 2017 Stock Incentive Plan (Filed With SEC on October 6, 2017)

Form of Restricted Stock Agreement under 2017 Stock Incentive Plan (Filed With SEC on October 6, 2017)

Form of Director and Officer Indemnification Agreement (Filed With SEC on October 6, 2017)

Letter Agreement, dated June 24, 2015, by and between the Registrant and John Tomayko, M.D (Filed With SEC on October 6, 2017)

Termination and Release, dated April 14, 2017, by and between the Registrant and John Tomayko, M.D (Filed With SEC on October 6, 2017)

Lease Agreement, dated August 24, 2015, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC with respect to 675 Massachusetts Avenue (Filed With SEC on October 6, 2017)

Sublease, dated July 6, 2016, by and between the Registrant and Tetraphase Pharmaceuticals, Inc. with respect to 480 Arsenal Street (Filed With SEC on October 6, 2017)

Stock Purchase Agreement, dated June 6, 2016, by and among Spero Cantab, Inc., the Registrant, Spero Cantab UK Limited, PBB Distributions Limited, New Pharma License Holdings... (Filed With SEC on October 6, 2017)

Assignment and License Agreement, dated May 9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on October 6, 2017)

License Agreement, dated June 14, 2017, by and between the Registrant and Meiji Seika Pharma Co., Ltd., as supplemented by Addendum to License Agreement, dated June 14, 2017 (Filed With SEC on October 6, 2017)

Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.) (Filed With SEC on October 6, 2017)

Category

Industry

Companies

Contracts

Spero Therapeutics, Inc. Contracts & Agreements